Study of Exelon Transdermal Patch in Amnestic Mild Cognitive Impairment Patients
| Status: | Completed |
|---|---|
| Conditions: | Cognitive Studies |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 55 - 85 |
| Updated: | 10/2/2013 |
| Start Date: | June 2011 |
| End Date: | May 2015 |
| Contact: | Christine Reece, B.S., CCRP |
| Email: | raolab@ccf.org |
| Phone: | 216-445-9009 |
24-week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Exelon® [Rivastigmine] Transdermal Patch in 120 APOE e4 Positive Amnestic MCI Patients
The goal of this project is to determine if task-activated fMRI is sensitive to the central
cholinergic deficit associated with Mild Cognitive Impairment.
Inclusion Criteria:
- Diagnosis of amnestic MCI
- In good general health with no diseases expected to interfere with the study
- Ability to undergo MRI
- Fluent in English
- Stable prescription dosages 1 month prior to testing
- Carrier of the APOE e4 allele (determined by blood draw at screening visit)
Exclusion Criteria:
- Neurological illness/conditions
- Medical illnesses/conditions that may affect brain function
- Prior history of use of any cholinesterase inhibitor
- Instable or severe cardiovascular disease or asthmatic condition
We found this trial at
1
site
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
Click here to add this to my saved trials
